{"id":4512,"date":"2025-03-31T18:12:10","date_gmt":"2025-03-31T18:12:10","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/human-normal-immunoglobulin-txt\/"},"modified":"2025-03-31T18:12:10","modified_gmt":"2025-03-31T18:12:10","slug":"human-normal-immunoglobulin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/human-normal-immunoglobulin-txt\/","title":{"rendered":"human normal immunoglobulin.txt"},"content":{"rendered":"<p><H3>  CLINICAL USE <\/H3><br \/>\nReplacement therapy in primary and  secondary immunodeficiencyIdiopathic thrombocytopenic purpura Guillain Barr\u00e9 syndrome Kawasaki disease Allogeneic bone marrow transplantation Treatment of infections and prophylaxis of  graft versus host disease<H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3>Variable according to preparation and indication. See individual SPC<H3>  PHARMACOKINETICS    <\/H3><LI> Molecular weight &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :150 000<\/li>\n<li>  %Protein binding  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp  &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :\u2013<\/li>\n<li>  %Excreted unchanged in urine &amp;nbsp &amp;nbsp : \u2013<\/li>\n<p><LI> Volume of distribution (L\/kg) &amp;nbsp &amp;nbsp &amp;nbsp :\u2013<\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&amp;nbsp &amp;nbsp &amp;nbsp :24\u201336 days<H3>  DOSE IN RENAL IMPAIRMENT <\/H3> <H4>GFR (mL\/MIN)<\/H4><LI> 20 to 50  &amp;nbsp &amp;nbsp : Dose as normal renal function<LI> 10 to 20  &amp;nbsp &amp;nbsp : Dose as normal renal function<LI> &lt;10 &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : Dose as normal renal function. See \u2018Other Information\u2019<H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3><LI> CAPD  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp:Not dialysed. Dose as in normal renal function<\/p>\n<li> HD &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :Not dialysed. Dose as in normal renal function<LI>HDF\/high flux  &amp;nbsp :Probably not dialysed. Dose as in normal renal function<LI>CAV\/VVHD  &amp;nbsp &amp;nbsp &amp;nbsp:Probably not dialysed. Dose as in normal renal function<H3> IMPORTANT DRUG INTERACTIONS  <\/H3>Potentially hazardous interactions with other drugsImmunoglobulin administration may  impair (for a period of at least 6 weeks and up to 3 months) the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella<H3> ADMINISTRATION  <\/H3><H4> Reconstition<\/H4>\u2013<H4>  Route  <\/H4>IV <H4>  Rate of Administration  <\/H4>Variable \u2013 see individual SPC <H4>Comments<\/H4> <H4>  OTHER INFORMATION  <\/H4>IgG and IgG-complexes are broken down  in the cells of the reticuloendothelial systemCases of acute renal failure have been  reported in patients receiving IVIg therapy. In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolaemia, overweight, concomitant nephrotoxic medicinal products or, aged over 65. In all patients, IVIg administration requires:adequate hydration prior to the  \u2014initiation of the infusion of IVIg;monitoring of urine output; \u2014 monitoring of serum creatinine levels; \u2014avoidance of concomitant use of loop  \u2014diureticsIn case of renal impairment, IVIg  discontinuation should be considered. While reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IVIg products, those containing sucrose (compared to glycine, maltose or sorbitol) as a stabiliser accounted for a disproportionate share of the total number. In patients at risk, the use of IVIg products that do not contain sucrose may be considered. In addition, the product should be administered at the minimum concentration and infusion rate practicableOverdose may lead to fluid overload and  hyperviscosity, particularly in patients at risk, including elderly patients or patients with renal impairmentThe MHRA has issued a Medical Device  Alert relating to the following point of care and home-use blood glucose meters: Roche Accu-Chek and Glucotrend, Abbott Diabetes Care FreeStylenormal human immunoglobulin.norMAL hUMAn iMMUnoGLoBULin 531There is a risk of overestimation of  \u2014blood glucose results when these meters are used for samples from patients on treatments that contain (or are metabolised to) maltose, xylose or galactose. The MHRA advises that the affected meters should not be used to measure blood glucose in patients receiving such treatments. Treatments that are known to contain (or that are metabolised to) maltose, xylose or galactose include (Extraneal\u00ae) icodextrin (used in peritoneal dialysis, PD), and certain immunoglobulin preparations (including Octagam\u00ae).<br \/>\n","protected":false},"excerpt":{"rendered":"<p>CLINICAL USE Replacement therapy in primary and secondary immunodeficiencyIdiopathic thrombocytopenic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4512","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4512"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4512\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}